高级别B细胞淋巴瘤非特指型诊断的观察者间一致性差:LLMPP研究
本研究由淋巴瘤/白血病分子分析项目(LLMPP)的血液病理专家对92例初诊为高级别B细胞淋巴瘤非特指型(HGBCL, NOS)的病例进行独立和共识复习,发现仅42%的病例最终确诊为HGBCL, NOS,观察者间一致性差,且分子特征无显著差异,提示该诊断类别可能非独立疾病实体。
要点
- HGBCL, NOS形态学诊断重复性差,仅42%初诊病例被确认。
- 独立复习中33%病例确认,14%被重新分类为DLBCL。
- 确诊与未确诊病例在DZsig表达、MYC重排等方面无显著差异。
核心结论
- HGBCL, NOS的形态学诊断观察者间一致性差,仅42%的初诊病例被确认。
- HGBCL, NOS可能不代表独立的临床病理实体,需更客观的生物学标志物如DZsig来区分。
研究设计与样本
- LLMPP的血液病理专家复习92例初诊为HGBCL, NOS的病例。
- 至少3/4的专家独立确认诊断,其余病例由10-15名病理学家组成的共识小组联合复习。
主要发现
- 独立复习中,30/92(33%)的病例被至少3/4的专家确认,13例(14%)被重新分类为DLBCL。
- 共识小组额外确认9例HGBCL, NOS,最终共39/92(42%)的初诊病例被确认。
- 初诊队列与最终确认队列在暗区特征(DZsig)表达、MYC重排频率和细胞起源等方面无显著差异。
临床怎么用
- HGBCL, NOS的诊断需谨慎,形态学标准重复性差,建议结合分子特征如DZsig。
- 对于疑似HGBCL, NOS的病例,应考虑多学科会诊或共识复习以提高诊断准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-grade B-cell lymphoma, not otherwise specified (HGBCL, NOS), is defined by morphologic features intermediate between Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL). Lymphomas with a complex 11q aberration or concurrent MYC- and BCL2- or BCL6- rearrangements are excluded from this category. However, the reproducibility of the diagnosis of HGBCL, NOS is unknown to date. Expert hematopathologists of the Lymphoma/Leukemia Molecular Profiling Project reviewed 92 cases submitted as HGBCL, NOS. At least 3/4 hematopathologists reviewing cases independently confirmed the diagnosis in 30/92 (33%) cases, while 13 cases (14%) were reclassified as DLBCL. The remaining 49 cases were jointly reviewed by the consensus panel of 10 to 15 pathologists, confirming an additional 9 HGBCL, NOS. The remaining cases were reclassified as DLBCL or other aggressive B-cell lymphomas or were excluded due to insufficient material. In aggregate, only 39/92 (42%) of initially submitted cases were confirmed as HGBCL, NOS, demonstrating poor interobserver agreement. Interestingly, however, there were no significant differences between the initially submitted cohort and those ultimately confirmed by the pathology review panel concerning dark zone signature (DZsig) expression, frequency of MYC -rearrangements and cell of origin, among others. Despite the finding that pathologists can identify cytomorphological features associated with adverse biological characteristics, the poor reproducibility of high-grade morphology and molecular heterogeneity suggests that HGBCL, NOS does not represent a distinct clinicopathologic entity and that more objective markers of distinct biologic features, such as the DZsig, may better separate cases into relevant diagnostic categories than morphology alone.
引用
- Kurz KS, Ondrejka SL, Collinge B, et al. Challenges in Diagnosing High-grade B-cell Lymphoma, NOS: Poor Interobserver Agreement on Its Morphologic Definition-An LLMPP Study. Am J Surg Pathol. 2026. PMID: 42138053. doi:10.1097/PAS.0000000000002565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。